Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
No it isn't
The only possible 'legitimate' reason that SNG could delay releasing results would be that it would compromise a commercially active & ongoing negotiation. That would only be a takeover or major licensing deal!!
Bad results don't qualify.
So if you believe that negotiations are ongoing then yes, that would justify delaying the results. That is a big stretch, but possible I suppose
This the most stupid thread title I have ever seen on LSE, and boy, that is a record had to claim!
The company, until possibly thursday or friday just gone, has not seen the data. If you believe otherwise you know sweet FA about clinical trials. Nor do you know anything about the commercially sensitive data rules for AIM companies. In which case why are you investing? Or are you just gambling, like so many others.
RM is on record as saying they will release news as soon as they can. AIM rules COMPEL them to do so, with some very restricted and specific reasons that allow any delay.
Go away and infest someone else's investments
al lot of pi will sell in the market at, or even above any 'offer' price and not wait for the deal to be finalised.
who cares?
On successful P3 results, all bets are off, it will be the highest bidder that will drive the sp! Earnings will not be relevant unless RM rejects all bids and decides to go it alone. Which is a possibility, fairly remote, but still possible
the submission date for the conference data was early september. Delta will be in the Phase 3 results, Omicron wasn't around. But.... delegates have a 3 min q&a. The RNS publication will allow Phil to speak freely if asked about delta & omicron
that's only because they are cr4p at sequencing and only do a fraction of the level we do in this country 7 elsewhere
If they are brand new, that would be the required amounts
It is always possible they are not brand new, but have started buying again. In which case, who knows what they need?
If UK based - 3%
If non-UK -5%
Bet our friend Robert is having such a fun day on the Golf course today! ;-)
.
It is very difficult to understand the MSCI selection criteria. #SNG is not a gambe now, but #SYME was included and that is an absolute basket case of a company!!
tiger is backed with feaces, not faces
What a plonker
didn't mean to post it twice! ;-)
SYNAIRGEN (BUY, 990p) Pfizer data - SNG down 12%. Shortly after the UK approval of Merck’s Molnupiravir (50% reduction in hospitalisations), Pfizer has reported an 89% reduction in hospitalisations or deaths following a course of treatment with PF-07321332, a protease inhibitor that interferes with viral replication. As with Merck’s pill, there are some concerns over potential future emergence of variants that become drug-resistant as with HIV-1 protease inhibitors. Impressively, Pfizer expects $50bn in sales from vaccines and pre-market indications suggest a 10% rise in market cap on this data equivalent to $25bn, showing the continued need for treatments despite global mass vaccinations. Exclusion criteria in this study include patients with oxygen saturation <92%, and so largely excludes patients that may require SNG001. We would also anticipate increasing regulatory scrutiny on these data in light of the emerging issues with Pfizer’s vaccine studies as reported in the British Medical Journal. As with Merck, we see continued need for a broad range of medications to treat increasingly vaccine and biologic resistant variants and continue to see an urgent need for SNG001 in the broader treatment armoury.
SYNAIRGEN (BUY, 990p) Pfizer data - SNG down 12%. Shortly after the UK approval of Merck’s Molnupiravir (50% reduction in hospitalisations), Pfizer has reported an 89% reduction in hospitalisations or deaths following a course of treatment with PF-07321332, a protease inhibitor that interferes with viral replication. As with Merck’s pill, there are some concerns over potential future emergence of variants that become drug-resistant as with HIV-1 protease inhibitors. Impressively, Pfizer expects $50bn in sales from vaccines and pre-market indications suggest a 10% rise in market cap on this data equivalent to $25bn, showing the continued need for treatments despite global mass vaccinations. Exclusion criteria in this study include patients with oxygen saturation <92%, and so largely excludes patients that may require SNG001. We would also anticipate increasing regulatory scrutiny on these data in light of the emerging issues with Pfizer’s vaccine studies as reported in the British Medical Journal. As with Merck, we see continued need for a broad range of medications to treat increasingly vaccine and biologic resistant variants and continue to see an urgent need for SNG001 in the broader treatment armoury.
From the press release "In Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said."
So no claims as to effect if started outside of the 3-5 day window. I would like to see the numbers for someone starting at day 6,7, 8, 9 etc. It is very easy to be selective with newspaper releases.
All friday messages disappeared!!
The SNG drug, SNG001, is an inhaled Interferon-beta formulation that supports the natural interferon immune system in the lungs. So, no, it is completely different (I believe as I am no scientist).
It is a good job it is different as they have been in human trials for a number of years pre-covid (for COPD and Asthma) and now have 2 phase 3 trials running , one for Hospitalised patients (coming to an end soon) and now Phase 3 for home based outpatients just starting (and funded by the US Government!) So they are streets ahead of us in terms of getting close to a commercialsed drug.
Another great addition to the #SNG Team!!!
If not seen before, this is worth a read. Draw your own conclusions :-)
Lots of Pharmas have weak patent futures that they are all looking to reinforce. The money is out there. Read this analysis from the FT. https://archive.fo/uHpes